Additionally, cabozantinib, an oral TKI targeting MET, VEGFR2, and Axl, is being studied in combination with the anti-PD-L1 agent durvalumab in advanced gastroesophageal cancers, including gastric cancer, in a phase I/II open-label multi-cohort trial (NCT03539822). Here, MET is linked to gastric cancer.